ArticlePharmaceutics2022

Short-Interval, Low-Dose Peptide Receptor Radionuclide Therapy in Combination with PD-1 Checkpoint Immunotherapy Induces Remission in Immunocompromised Patients with Metastatic Merkel Cell Carcinoma.

Alexandra Aicher et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.